13种氟喹诺酮类药物对具有gyrA、gyrB、grlA和norA特征性突变的金黄色葡萄球菌分离株及野生型分离株的体外活性。
In vitro activities of 13 fluoroquinolones against Staphylococcus aureus isolates with characterized mutations in gyrA, gyrB, grlA, and norA and against wild-type isolates.
作者信息
Muñoz Bellido J L, Alonso Manzanares M A, Yagüe Guirao G, Gutiérrez Zufiaurre M N, Toldos M C, Segovia Hernández M, Garcia-Rodríguez J A
机构信息
Departamento de Microbiología, Hospital Universitario de Salamanca, Spain.
出版信息
Antimicrob Agents Chemother. 1999 Apr;43(4):966-8. doi: 10.1128/AAC.43.4.966.
Abstract
The in vitro activities of 13 fluoroquinolones (FQs) were tested against 90 Staphylococcus aureus clinical isolates: 30 wild type for gyrA, gyrB, grlA and norA and 60 with mutations in these genes. Clinafloxacin (CI-960), sparfloxacin, and grepafloxacin were the most active FQs against wild-type isolates (MICs at which 90% of isolates were inhibited, 0.06 to 0.1 microgram/ml). Mutations in grlA did not affect the MICs of newer FQs. grlA-gyrA double mutations led to higher MICs for all the FQs tested. Efflux mechanisms affected the newer FQs to a much lesser extent than the less recently developed FQs.
摘要
测试了13种氟喹诺酮类药物（FQ）对90株金黄色葡萄球菌临床分离株的体外活性：30株gyrA、gyrB、grlA和norA基因野生型菌株，以及60株这些基因发生突变的菌株。克林沙星（CI-960）、司帕沙星和格帕沙星是对野生型分离株活性最强的氟喹诺酮类药物（90%分离株被抑制时的最低抑菌浓度，0.06至0.1微克/毫升）。grlA基因突变不影响新型氟喹诺酮类药物的最低抑菌浓度。grlA-gyrA双突变导致所有测试氟喹诺酮类药物的最低抑菌浓度升高。与早期开发的氟喹诺酮类药物相比，外排机制对新型氟喹诺酮类药物的影响要小得多。
相似文献
1
In vitro activities of 13 fluoroquinolones against Staphylococcus aureus isolates with characterized mutations in gyrA, gyrB, grlA, and norA and against wild-type isolates.13种氟喹诺酮类药物对具有gyrA、gyrB、grlA和norA特征性突变的金黄色葡萄球菌分离株及野生型分离株的体外活性。
Antimicrob Agents Chemother. 1999 Apr;43(4):966-8. doi: 10.1128/AAC.43.4.966.
2
Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus.耐甲氧西林金黄色葡萄球菌喹诺酮耐药临床分离株中gyrA和grlA基因的突变
J Antimicrob Chemother. 1996 Sep;38(3):543-6. doi: 10.1093/jac/38.3.543.
3
Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA.在金黄色葡萄球菌菌株中，外排泵介导的对喹诺酮类药物的耐药性，这些菌株的gyrA、gyrB、grlA和norA为野生型。
Antimicrob Agents Chemother. 1999 Feb;43(2):354-6. doi: 10.1128/AAC.43.2.354.
4
Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.曲伐沙星与其他氟喹诺酮类药物对金黄色葡萄球菌纯化的拓扑异构酶以及gyrA和grlA突变体的活性比较。
Antimicrob Agents Chemother. 1999 Aug;43(8):1845-55. doi: 10.1128/AAC.43.8.1845.
5
6
Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.116株无亲缘关系的金黄色葡萄球菌临床分离株中，环丙沙星、氧氟沙星、左氧氟沙星、司帕沙星和莫西沙星（BAY 12 - 8039）的最低抑菌浓度（MIC）与grlA、grlB、gyrA和gyrB基因突变之间的关系
J Antimicrob Chemother. 1998 Apr;41(4):481-4. doi: 10.1093/jac/41.4.481.
7
Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.新型氟喹诺酮类药物对肺炎链球菌临床分离株的活性，包括那些gyrA、parC和parE基因座发生突变的分离株。
Antimicrob Agents Chemother. 1999 Feb;43(2):329-34. doi: 10.1128/AAC.43.2.329.
8
Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.喹诺酮耐药性的分子流行病学及新型喹诺酮类药物对欧洲金黄色葡萄球菌分离株的体外活性比较
FEMS Immunol Med Microbiol. 1999 Dec;26(3-4):281-7. doi: 10.1111/j.1574-695X.1999.tb01400.x.
9
Characterization of sparfloxacin-resistant mutants of Staphylococcus aureus obtained in vitro.体外获得的金黄色葡萄球菌对司帕沙星耐药突变株的特性研究
Int J Antimicrob Agents. 2001 Aug;18(2):107-12. doi: 10.1016/s0924-8579(01)00366-1.
10
Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002.2002年分离出的耐甲氧西林金黄色葡萄球菌中对氟喹诺酮类药物的敏感和耐药基因
Int J Antimicrob Agents. 2005 May;25(5):374-9. doi: 10.1016/j.ijantimicag.2004.11.016.
引用本文的文献
1
The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.抗耐甲氧西林金黄色葡萄球菌喹诺酮类药物WCK 771对序贯选择的突变体具有强大活性，对耐喹诺酮金黄色葡萄球菌的突变选择窗较窄，且优先靶向DNA旋转酶。
Antimicrob Agents Chemother. 2006 Nov;50(11):3568-79. doi: 10.1128/AAC.00641-06. Epub 2006 Aug 28.
2
In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci.六种喹诺酮类药物的体外活性及金黄色葡萄球菌和凝固酶阴性葡萄球菌的耐药机制
Antimicrob Agents Chemother. 2001 May;45(5):1553-7. doi: 10.1128/AAC.45.5.1553-1557.2001.
3
Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria.革兰氏阳性菌和分枝杆菌中由外排介导的对氟喹诺酮类药物的耐药性。
Antimicrob Agents Chemother. 2000 Oct;44(10):2595-9. doi: 10.1128/AAC.44.10.2595-2599.2000.
4
Mutation frequencies and antibiotic resistance.突变频率与抗生素耐药性。
Antimicrob Agents Chemother. 2000 Jul;44(7):1771-7. doi: 10.1128/AAC.44.7.1771-1777.2000.
本文引用的文献
1
Structure of grepafloxacin relative to activity and safety profile.格帕沙星的结构与活性及安全性概况的关系。
Clin Microbiol Infect. 1998 Mar;4 Suppl 1:S15-S20. doi: 10.1111/j.1469-0691.1998.tb00684.x.
2
Grepafloxacin: microbiological properties.格帕沙星：微生物学特性。
Clin Microbiol Infect. 1998 Mar;4 Suppl 1:S9-S14. doi: 10.1111/j.1469-0691.1998.tb00683.x.
3
Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.116株无亲缘关系的金黄色葡萄球菌临床分离株中，环丙沙星、氧氟沙星、左氧氟沙星、司帕沙星和莫西沙星（BAY 12 - 8039）的最低抑菌浓度（MIC）与grlA、grlB、gyrA和gyrB基因突变之间的关系
J Antimicrob Chemother. 1998 Apr;41(4):481-4. doi: 10.1093/jac/41.4.481.
4
Analysis of grlA mutations in clinical isolates of Staphylococcus aureus with different levels of quinolone resistance.对不同喹诺酮耐药水平的金黄色葡萄球菌临床分离株中grlA基因突变的分析。
Antimicrob Agents Chemother. 1998 May;42(5):1306-7. doi: 10.1128/AAC.42.5.1306.
5
Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.金黄色葡萄球菌拓扑异构酶IV和DNA促旋酶的突变：对喹诺酮和香豆素活性的新型多效性影响。
Antimicrob Agents Chemother. 1998 Jan;42(1):121-8. doi: 10.1128/AAC.42.1.121.
6
Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.司帕沙星对肺炎链球菌中DNA回旋酶的靶向作用：喹诺酮类药物对回旋酶或拓扑异构酶IV的选择性靶向作用
Antimicrob Agents Chemother. 1997 Feb;41(2):471-4. doi: 10.1128/AAC.41.2.471.
7
Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli.关于parC突变在大肠杆菌高水平氟喹诺酮耐药性形成中作用的遗传学证据。
Antimicrob Agents Chemother. 1996 Apr;40(4):879-85. doi: 10.1128/AAC.40.4.879.
8
Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus.喹诺酮类药物的亲水性并非金黄色葡萄球菌外排介导耐药突变体活性降低的唯一因素。
Antimicrob Agents Chemother. 1996 Aug;40(8):1835-42. doi: 10.1128/AAC.40.8.1835.
9
Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli.喹诺酮耐药性大肠埃希菌临床分离株中parC基因突变的检测
Antimicrob Agents Chemother. 1996 Feb;40(2):491-3. doi: 10.1128/AAC.40.2.491.
10
Topoisomerase IV is a target of quinolones in Escherichia coli.拓扑异构酶IV是喹诺酮类药物在大肠杆菌中的作用靶点。
Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11801-5. doi: 10.1073/pnas.92.25.11801.
Zotero 插件